Zoetis Launches 75-Day Cytopoint Plus for Dog Allergies
Zoetis has received USDA licensing for Cytopoint Plus, a monoclonal antibody that provides 75 days of relief for canine allergic dermatitis.

Zoetis Inc. has launched Cytopoint Plus, a new monoclonal antibody for canine allergic dermatitis. The product, licensed by the USDA on November 11, 2026, is administered subcutaneously every 75 days. This interval is the longest of any licensed monoclonal antibody for this condition, offering a significant extension over the original Cytopoint product's four- to eight-week schedule. The injection provides 75 days of allergic itch relief in a single dose, aiming to eliminate the need for frequent clinic visits.
How It Works and Clinical Benefits
Cytopoint Plus was developed from Cytopoint with an enhanced duration of action. It works by targeting and neutralizing interleukin-31 (IL-31), a key protein that triggers itch signals. The product starts relieving allergic itch within one day of administration.
Clinical studies demonstrated its efficacy through day 75, with a safety profile similar to the original Cytopoint. In some dogs, reduced itch scores compared with controls were observed through day 90.
Adherence and Practical Advantages
The extended 75-day dosing interval directly addresses a major challenge in managing chronic canine allergies: treatment adherence. Frequent clinic visits can create logistical problems for pet owners, potentially leading to missed appointments and doses, which in turn can cause preventable flare-ups.
Lindsay McKay, DVM, DACVD, noted that "frequent visits can create scheduling hurdles for clients, which may contribute to missed treatments." The longer interval is designed to make long-term care more manageable. Tiffany Tapp, DVM, DACVD, added that "a longer gap between injections may make ongoing care more manageable and potentially more affordable for some families."
Indication and Market Position
Cytopoint Plus is indicated specifically for the treatment of allergic dermatitis in dogs. It is the first and only USDA-licensed monoclonal antibody for this specific condition. This differs from the original Cytopoint, which is labeled for both allergic and atopic dermatitis.
The need for such treatments is substantial. Allergic dermatitis is the number one reason pet owners visit veterinarians. Approximately one in four dogs presented for veterinary care experiences itching, and about 15 to 20 percent of those itchy dogs are diagnosed with allergic dermatitis.
Cytopoint Plus joins Cytopoint and Apoquel in Zoetis's portfolio of canine dermatology products. The development follows recent updated international guidelines for managing canine atopic dermatitis, which highlighted adherence challenges with existing therapies. The new injection eliminates the need for frequent clinic visits for allergic dermatitis treatment.





